scholarly journals Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands

2019 ◽  
Vol 24 (18) ◽  
Author(s):  
Alies van Lier ◽  
Brechje de Gier ◽  
Scott A McDonald ◽  
Marie-Josée J. Mangen ◽  
Maarten van Wijhe ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
The Netherlands ◽  
Immunisation Programme ◽  
Current Approach ◽  
Published Data ◽  
Uncertainty Interval ◽  
National Immunisation Programme ◽  
Vaccine Preventable Diseases ◽  
National Immunisation ◽  
Life Years

Introduction Estimating burden of disease (BoD) is an essential first step in the decision-making process on introducing new vaccines into national immunisation programmes (NIPs). For varicella, a common vaccine-preventable disease, BoD in the Netherlands was unknown. Aim To assess national varicella BoD and compare it to BoD of other vaccine-preventable diseases before their introduction in the NIP. Methods In this health estimates reporting study, BoD was expressed in disability-adjusted life years (DALYs) using methodology from the Burden of Communicable Diseases in Europe (BCoDE)-project. As no parameters/disease model for varicella (including herpes zoster) were available in the BCoDE toolkit, incidence, disease progression model and parameters were derived from seroprevalence, healthcare registries and published data. For most other diseases, BoD was estimated with existing BCoDE-parameters, adapted to the Netherlands if needed. Results In 2017, the estimated BoD of varicella in the Netherlands was 1,800 (95% uncertainty interval (UI): 1,800–1,900) DALYs. Herpes zoster mainly contributed to this BoD (1,600 DALYs; 91%), which was generally lower than the BoD of most current NIP diseases in the year before their introduction into the NIP. However, BoD for varicella was higher than for rotavirus gastroenteritis (1,100; 95%UI: 440–2,200 DALYs) and meningococcal B disease (620; 95%UI: 490–770 DALYs), two other potential NIP candidates. Conclusions When considering the introduction of a new vaccine in the NIP, BoD is usually estimated in isolation. The current approach assesses BoD in relation to other vaccine-preventable diseases’ BoD, which may help national advisory committees on immunisation and policymakers to set vaccination priorities.

scholarly journals Præventis, the immunisation register of the Netherlands: a tool to evaluate the National Immunisation Programme

2012 ◽  
Vol 17 (17) ◽  
Author(s):  
A van Lier ◽  
P Oomen ◽  
P de Hoogh ◽  
I Drijfhout ◽  
B Elsinghorst ◽  
...  
Keyword(s):  
The Netherlands ◽  
Immunisation Programme ◽  
National Immunisation Programme ◽  
National Immunisation ◽  
Binary File

Binary file ES_Abstracts_Final_ECDC.txt matches

scholarly journals Increased mumps incidence in the Netherlands: Review on the possible role of vaccine strain and genotype

2008 ◽  
Vol 13 (26) ◽  
Author(s):  
P Kaaijk ◽  
B A van der Zeijst ◽  
M C Boog ◽  
C W Hoitink
Keyword(s):  
The Netherlands ◽  
Vaccine Strain ◽  
Vaccination Coverage ◽  
Immunisation Programme ◽  
Religious Community ◽  
Recent Issue ◽  
National Immunisation Programme ◽  
National Immunisation ◽  
Geographic Regions

As reported in a recent issue of Eurosurveillance, a mumps outbreak is ongoing in the Netherlands despite high vaccination coverage of 90-95% [1]. The reported mumps cases are restricted to geographic regions with a high percentage of residents who are members of a religious community that rejects vaccination. Consequently, two thirds of the mumps patients were not vaccinated. However, also vaccinated individuals in these regions were affected [1]. Since 1987, the measles-mumps-rubella (MMR) combination vaccine produced by the Netherlands Vaccine Institute (NVI) is part of the Dutch national immunisation programme and administered at the ages of 14 months and nine years.

scholarly journals Rotavirus vaccine impact assessment surveillance in India: protocol and methods

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e024840 ◽  
Author(s):  
Nayana P Nair ◽  
Samarasimha Reddy N ◽  
Sidhartha Giri ◽  
Venkata Raghava Mohan ◽  
Umesh Parashar ◽  
...  
Keyword(s):  
Data Entry ◽  
Immunisation Programme ◽  
Ethics Committees ◽  
Rotavirus Vaccine ◽  
Routine Immunisation ◽  
National Immunisation Programme ◽  
National Immunisation ◽  
Institutional Ethics ◽  
Institutional Review ◽  
Vaccine Impact

IntroductionRotavirus infection accounts for 39% of under-five diarrhoeal deaths globally and 22% of these deaths occur in India. Introduction of rotavirus vaccine in a national immunisation programme is considered to be the most effective intervention in preventing severe rotavirus disease. In 2016, India introduced an indigenous rotavirus vaccine (Rotavac) into the Universal Immunisation Programme in a phased manner. This paper describes the protocol for surveillance to monitor the performance of rotavirus vaccine following its introduction into the routine childhood immunisation programme.MethodsAn active surveillance system was established to identify acute gastroenteritis cases among children less than 5 years of age. For all children enrolled at sentinel sites, case reporting forms are completed and a copy of vaccination record and a stool specimen obtained. The forms and specimens are sent to the referral laboratory for data entry, analysis, testing and storage. Data from sentinel sites in states that have introduced rotavirus vaccine into their routine immunisation schedule will be used to determine rotavirus vaccine impact and effectiveness.Ethics and disseminationThe Institutional Review Board of Christian Medical College, Vellore, and all the site institutional ethics committees approved the project. Results will be disseminated in peer-reviewed journals and with stakeholders of the universal immunisation programme in India.

scholarly journals Trust in Government and Covid-19 Vaccine Hesitancy

2021 ◽  
Vol 17 (3) ◽  
Author(s):  
Kate C. Prickett ◽  
Simon Chapple
Keyword(s):  
New Zealand ◽  
General Population ◽  
Immunisation Programme ◽  
High Population ◽  
Vaccine Hesitancy ◽  
Trust In Government ◽  
National Immunisation Programme ◽  
National Immunisation ◽  
Trust In Institutions

The long-term success of New Zealand’s Covid-19 elimination plan and the re-opening of fortress New Zealand rests on high population uptake of the Covid-19 vaccine. Understanding factors that contribute to vaccine hesitancy – and potential inequities in access and uptake – are consequently essential for the efficacy of the national immunisation programme which began rolling out to the general population in July 2021. Prior research on the New Zealand context has documented socio-demographic disparities in Covid-19 vaccine hesitancy (Horizon Research, 2020; Prickett, Habibi and Atatoa Carr, 2021; Thaker, 2021). However, little research has been undertaken to examine how psychosocial elements – such as people’s trust in institutions – might be associated with people’s vaccine intent and cast some light on the reasons underpinning their intent.

scholarly journals Mumps in Poland in 2018

2020 ◽  
pp. 406-410
Keyword(s):  
Vaccination Coverage ◽  
Surveillance System ◽  
Descriptive Analysis ◽  
Immunisation Programme ◽  
Common Disease ◽  
Mmr Vaccine ◽  
National Immunisation Programme ◽  
National Immunisation ◽  
Dose Scheme ◽  
Epidemiological Situation

INTRODUCTION. Vaccination against mumps from 2003 is mandatory in Poland and given as two dose scheme with MMR vaccine (mumps, measles, and rubella). Earlier this vaccination was only recommended. Despite observed decline in mumps incidence for over a decade which is a result of conducted vaccinations, mumps is still a common disease among the children. AIM. To assess epidemiological situation of mumps in Poland in 2018, including vaccination coverage in Polish population, in comparison to previous years. METHODS. The descriptive analysis was based on data retrieved from routine mandatory surveillance system and published in the annual bulletins “Infectious diseases and poisonings in Poland in 2018” and “Vaccinations in Poland in 2018”. RESULTS. In total, there were 1 585 mumps cases registered in Poland in 2018. Incidence of mumps was 4.1 per 100,000 and it was lower in comparison with 2017. The highest incidence (6.6 per 100 000) was registered in Opolskie voivodeship and the lowest (2.6) – in Warmińsko-mazurskie voivodeship. The highest incidence rate was observed among children aged 5 years (39.2 per 100 000). Incidence in men (5.0 per 100 000) was higher than in women (3.4). In 2018, 28 people were hospitalized due to mumps. Vaccination coverage of children aged 3 years in Poland in 2018 was 92,9% and it was lower by 1.1% in comparison with year 2017. CONCLUSIONS. Systematic execution of mumps vaccination in accordance with the National Immunisation Programme resulted in a significant decrease in the number of registered cases. Due to the high vaccination coverage further decline in the number of cases is expected.

Sign in / Sign up

Export Citation Format

Share Document